Last reviewed 2026-05-26 · How we verify

VERARD

THE VERARD COMPANY · FDA-approved approved Quality 4/100

VERARD is a drug developed by THE VERARD COMPANY. It is currently FDA-approved.

VERARD, marketed by The Verard Company, holds a position in the pharmaceutical market with its key composition patent set to expire in 2028. The drug's primary strength lies in its current market presence, leveraging its established patient base and brand recognition. The primary risk facing VERARD is the potential increase in competition post-patent expiry, which could erode market share and revenue.

At a glance

Generic name	VERARD
Sponsor	THE VERARD COMPANY
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VERARD CI brief — competitive landscape report
VERARD updates RSS · CI watch RSS
THE VERARD COMPANY portfolio CI

Frequently asked questions about VERARD

What is VERARD?

VERARD is a pharmaceutical drug developed by THE VERARD COMPANY.

Who makes VERARD?

VERARD is developed and marketed by THE VERARD COMPANY (see full THE VERARD COMPANY pipeline at /company/the-verard-company).

What development phase is VERARD in?

VERARD is FDA-approved (marketed).

Manufacturer: THE VERARD COMPANY — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing